Unveiling the Hidden Secret: Sanofi's Dual Success Valued at 15.8 Billion USD

In the world of pharmaceutical giants, Sanofi has recently made waves with a groundbreaking acquisition that has raised eyebrows and captured attention across the industry. With clinical-stage products alone, the company secured a staggering payment of up to 2.2 billion USD (approximately 15.8 billion CNY). This extraordinary move involves Sanofi's acquisition of Inhibrx, a biotechnology company that holds immense appeal. Let's delve into the details and uncover the secret behind this remarkable dual success.

Sanofi's Unique Path:
Sanofi, the only French pharmaceutical company among the global top 10, has embarked on a distinctive development path when compared to other multinational pharmaceutical enterprises. According to its 2022 financial report, Sanofi's pharmaceutical business recorded total revenues of 37.917 billion euros. Specialty Care contributed 16.457 billion euros, General Medicines brought in 14.231 billion euros, and Vaccines generated 7.229 billion euros. It is worth noting that Sanofi stands out by not relying heavily on oncology or autoimmune diseases like psoriasis, arthritis, or Crohn's disease for its blockbuster products. Instead, it owes its success to Dupixent, a drug used to treat atopic dermatitis. Dupixent alone generated sales of 8.293 billion euros in 2022, accounting for 50.39% of the Specialty Care segment. This exceptional drug outperformed various other therapeutic areas, including neurology, immunology, rare diseases (including rare blood disorders), oncology, and vaccines.

Sanofi's Vaccine Sector:
Sanofi's vaccine division serves as a crucial pillar of its performance and has catapulted the company into the ranks of the global vaccine leaders. Before the COVID-19 pandemic in 2019, Sanofi held two prominent positions among the top 10 global vaccine sales. After facing intense competition in the vaccine landscape during the pandemic, Sanofi's vaccine division encountered challenges. The company's 2023 Q3 financial report revealed that its vaccine division generated 5.488 billion euros in revenue, a slight decline of 0.5% compared to the previous year. While the sales of other products showed a decline, the Boostervaccines, a category that includes COVID-19 booster shots, witnessed a 4.6% increase in sales. Despite losing the COVID-19 vaccine advantage enjoyed by Pfizer, which earned substantial profits, Sanofi's routine vaccines such as Prevnar, FSME-IMMUN, and Nimenrix continued to exhibit growth. Moreover, Sanofi's vaccine division revenue for the first three quarters of 2023 reached 10.388 billion USD, a 23.50% increase year-on-year. Similarly, GSK's vaccine division also experienced a 24% growth, with a 21% growth rate even after excluding COVID-19 products. Sanofi's vaccine division has received a boost with the approval of Beyfortus, the world's first and only preventive RSV medication for infants. Beyfortus, with its significant market demand in China, is expected to revitalize Sanofi's vaccine sector.

Inhibrx's Appeal:
Inhibrx specializes in developing novel biopharmaceutical candidates for oncology and rare diseases. Among its pipeline products, four have entered the clinical stage: INBRX-101, INBRX-109, INBRX-105, and INBRX-106. INBRX-101 and INBRX-109 are in Phase 2 clinical trials, while INBRX-105 and INBRX-106 are in Phase 1. Sanofi's acquisition of Inhibrx demonstrates its high regard for INBRX-101, as it is the only product that will be incorporated into Sanofi's pipeline.